Advanced wound care market projected to exceed $15 billion globally by 2030 PERTH, Australia , Feb. 12, 2025 /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF) has made significant progress in its collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care.
NEW YORK , Jan. 27, 2025 /PRNewswire/ -- A closed-end fund that invests in global equities using a disciplined value approach Average weekly trading volume of approximately 72,971 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience CLOSING PRICES AS OF 12/31/24 NAV 12.55 MKT 10.72 AVERAGE ANNUAL TOTAL RETURN AS OF 12/31/24 NAV (%) MKT (%) One-Month* -5.05 -5.03 One-Year 11.80 14.81 Three-Year -1.78 -4.18 Five-Year 5.69 5.57 10-Year 7.40 7.21 *Not Annualized Important Performance and Expense Information All performance information reflects past performance, is presented on a total return basis, and reflects the reinvestment of distributions. Past performance is no guarantee of future results.
PERTH, Australia , Jan. 7, 2025 /PRNewswire/ -- Argent BioPharma (ASX:RGT) (OTCQB:RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology. The company announces the successful completion of a US$4,500,000 (before costs) capital raise (Placement) through the subscription of 5,625,000 Units, each priced at US$0.80 (~A$1.28).
PERTH, Australia , Jan. 6, 2025 /PRNewswire/ -- Argent BioPharma (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology. The company announces the successful completion of a US$4,500,000 (before costs) capital raise (Placement) through the subscription of 5,625,000 Units, each priced at US$0.80 (~A$1.28).
NEW YORK , Nov. 20, 2024 /PRNewswire/ -- A closed-end fund that invests in global equities using a disciplined value approach Average weekly trading volume of approximately 27,933 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience CLOSING PRICES AS OF 10/31/24 NAV 13.24 MKT 11.50 AVERAGE ANNUAL TOTAL RETURN AS OF 10/31/24 NAV (%) MKT (%) One-Month* -1.34 -0.86 Year to Date* 12.97 17.95 One-Year 36.12 45.07 Three-Year -0.79 -2.95 Five-Year 7.85 8.80 10-Year 7.20 6.98 *Not Annualized Important Performance and Expense Information All performance information reflects past performance, is presented on a total return basis, and reflects the reinvestment of distributions. Past performance is no guarantee of future results.
NEW YORK , Oct. 28, 2024 /PRNewswire/ -- A closed-end fund that invests in global equities using a disciplined value approach Average weekly trading volume of approximately 28,421 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience CLOSING PRICES AS OF 09/30/24 NAV 13.42 MKT 11.60 AVERAGE ANNUAL TOTAL RETURN AS OF 09/30/24 NAV (%) MKT (%) One-Month* 0.22 -0.47 Year to Date* 14.51 18.97 One-Year 28.60 35.28 Three-Year 0.78 -1.90 Five-Year 8.95 9.55 10-Year 7.17 6.94 *Not Annualized Important Performance and Expense Information All performance information reflects past performance, is presented on a total return basis, and reflects the reinvestment of distributions. Past performance is no guarantee of future results.
NEW YORK , May 28, 2024 /PRNewswire/ -- A closed-end fund that invests in global equities using a disciplined value approach Average weekly trading volume of approximately 48,212 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience CLOSING PRICES AS OF 04/30/24 NAV 12.08 MKT 10.23 AVERAGE ANNUAL TOTAL RETURN AS OF 04/30/24 NAV (%) MKT (%) One-Month* -4.28 -4.30 Year to Date* 3.07 4.92 One-Year 15.65 18.76 Three-Year -2.24 -4.37 Five-Year 6.19 6.06 10-Year 5.65 5.36 *Not Annualized Important Performance and Expense Information All performance information reflects past performance, is presented on a total return basis, and reflects the reinvestment of distributions. Past performance is no guarantee of future results.
Royce Global Trust provides exposure to a globally diversified equity portfolio with a focus on small-cap companies. RGT trades at a rather wide discount, but relative to its historical levels, it doesn't look like too much of a deal today. RGT's performance has been mixed compared to its benchmark, but it could be an option for investors seeking some diversification.